Company profile

Anthony S. Marucci
Incorporated in
Fiscal year end
Former names
Avant Immunotherapeutics Inc, T Cell Sciences Inc
IRS number

CLDX stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


6 May 20
9 Jul 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 2.73M 887K 546K 715K
Net income -12.63M -10.45M -11.41M -11.78M
Diluted EPS -0.73 -0.64 -0.75 -0.84
Net profit margin -463% -1178% -2090% -1647%
Operating income -12.87M -12.99M -11.84M -12.26M
Net change in cash 11.49M -5.35M -3.16M -11.79M
Cash on hand 22.72M 11.23M 16.59M 19.74M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 3.57M 9.54M 12.74M 6.79M
Net income -50.88M -151.18M -93.03M -128.53M
Diluted EPS -3.51 -14.48 -10.86 -18.99
Net profit margin -1424% -1585% -730% -1894%
Operating income -55.03M -156.44M -121.53M -132.92M
Net change in cash 0 -13.08M -18.15M -29.65M
Cash on hand 11.23M 11.23M 24.31M 42.46M
Cost of revenue 100K 700K 700K 1.6M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No 10.38 14,400 149.47K 14,400
18 Jun 20 Wright Richard M. Incentive Stock Option Common Stock Grant Aquire A No 10.38 42,000 435.96K 42,000
18 Jun 20 Young Diane C. Incentive Stock Option Common Stock Grant Aquire A No 10.38 72,000 747.36K 72,000
9.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 43 47 -8.5%
Opened positions 7 6 +16.7%
Closed positions 11 14 -21.4%
Increased positions 10 11 -9.1%
Reduced positions 9 13 -30.8%
13F shares
Current Prev Q Change
Total value 5.95M 8.25M -27.8%
Total shares 3.55M 3.55M +0.0%
Total puts 13.4K 13K +3.1%
Total calls 39.3K 30K +31.0%
Total put/call ratio 0.3 0.4 -21.3%
Largest owners
Shares Value Change
Renaissance Technologies 1.17M $1.94M +4.9%
Vanguard 537.93K $893K +4.2%
Cresset Asset Management 457.67K $760K 0.0%
Dimensional Fund Advisors 345.92K $574K +3.3%
BLK BlackRock 344.48K $572K +0.7%
Acadian Asset Management 298.65K $496K +20.4%
Geode Capital Management 103.98K $172K 0.0%
Bridgeway Capital Management 50.2K $83K -35.1%
CS Credit Suisse 35.32K $58K NEW
NTRS Northern Trust 34.26K $57K -0.9%
Largest transactions
Shares Bought/sold Change
Renaissance Technologies 1.17M +54.82K +4.9%
Acadian Asset Management 298.65K +50.58K +20.4%
IVZ Invesco 0 -39.39K EXIT
CS Credit Suisse 35.32K +35.32K NEW
Susquehanna International 33.16K -28.55K -46.3%
Bridgeway Capital Management 50.2K -27.1K -35.1%
Stratos Wealth Partners 0 -25K EXIT
Vanguard 537.93K +21.81K +4.2%
A.R.T. Advisors 0 -21.54K EXIT
WINTON 12.03K -20K -62.4%

Financial report summary

Content analysis ?
H.S. freshman Avg
New words: abandoned, abandonment, adenocarcinoma, alsoNote, announced, anthony, ASC, behalf, China, CINDU, context, costimulation, couple, customer, declared, disagreement, doubt, driven, duly, economy, effort, enable, endedMarch, exhibit, expenditure, foreseeable, Furnished, Gilead, global, globally, halt, Health, herewith, HIV, implemented, index, instance, judgment, label, letter, Linkbase, linking, marucci, merger, merit, mitigating, notifying, ordinary, outbreak, pandemic, parental, pathway, platform, preventing, prolonged, rationale, registrant, satisfaction, Schema, scratching, service, shipping, spread, strain, subvert, successful, surfaced, Taxonomy, thereunto, Transaction, travel, undersigned, viability, world, Wuhan, XBRL, York
Removed: AACR, American, Amgen, applied, apply, approved, arise, arm, assessment, attack, August, Australia, beginning, biopsy, BMS, Board, Bone, borrowing, BRAF, cascade, classification, cold, combined, conducted, defend, Depending, diagnosed, discontinuation, effected, EGFR, eliminate, enhanced, European, exceeded, exercised, expectation, expired, expressing, expression, extend, fatigue, February, feet, fifteen, Final, Flow, Fremont, frequent, Frontier, function, gain, Glemba, goodwill, Hampton, headcount, hematologic, Herceptin, hold, immunologic, impacted, implicit, inception, incremental, induced, inhibited, inhibition, initial, Initiative, International, interval, investigational, journal, leased, leasing, malignant, Marrow, Mechanistic, method, minimum, mobilize, modified, modify, nausea, nivolumab, oncology, Opdivo, opportunity, ovarian, package, paired, par, patent, permissive, permitted, person, phosphorylated, pipeline, portion, practical, preliminary, premium, prepaid, published, qualitative, quantitative, radiation, reclassifying, reduced, reduction, registering, regulation, renew, require, resection, respond, restatement, retroactively, retrospective, retrospectively, reverse, select, separately, space, split, square, Squibb, stimulating, suggested, surgery, Tafinlar, Tarceva, terminate, termination, tested, TIL, transition, Transplantation, trended, updated, Vaccine, variable, varlilumab, vitro, vivo, xenograft, Zelboraf